Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYPAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYPAR.
ERYC vs ERYPAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
Intravenous: 100 mg every 12 hours for 7 to 14 days.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic